Telix Pharmaceuticals (TLX) investor relations material

Business overview and infrastructure

• Vertically integrated theranostic radiopharma model combines diagnostics and therapeutics for each target.

• Imaging business commercialized with $1 billion in annual sales, mainly from prostate cancer imaging; recent brain cancer approval adds to portfolio.

• Cash flow from imaging products funds a robust R&D pipeline, including three phase III trials.

• Major focus areas are urology and neuro-oncology, with global manufacturing and distribution infrastructure established since 2020.

• Delivered 3 million patient doses last year, demonstrating commercial scale.

Financial guidance and outlook

• Guidance for 2026 revised toward the upper end following a strong first half; current trajectory remains positive.

• No plans for casual guidance adjustments; maintaining current guidance for the year.

Precision medicine and imaging pipeline

• Pixclara, the first PET imaging agent for glioma, recently FDA approved; addresses a high unmet need in neuro-oncology.

• Market opportunity estimated at 20,000–25,000 scans, with potential for multiple scans per patient and significant upside.

• Expansion into metastatic brain tumor imaging could multiply the addressable market by four to five times.

• Synergies expected from existing relationships in nuclear medicine and neurology.